<DOC>
	<DOCNO>NCT02254447</DOCNO>
	<brief_summary>This study investigate relative bioavailability two candidate tablet formulation 16 milligram ( mg ) Candesartan cilexetil ( GW615775 ) compare reference product ATACANDâ„¢ contain 16 mg Candesartan cilexetil healthy human subject . This open-label , randomize , single dose , three-way crossover , six sequence study enrol 18 healthy human subject ensure least 14 subject complete study plan . Each subject enrol participate three treatment period assign one six treatment sequence , accordance randomization schedule . The treatment period separate washout period least 7 day 14 day dose occasion . A follow visit conduct 14-21 day post last dosing . ATACAND register trademark AstraZeneca group company .</brief_summary>
	<brief_title>Relative Bioavailability Study Candesartan Cilexetil Under Fasting Conditions</brief_title>
	<detailed_description />
	<mesh_term>Respiration Disorders</mesh_term>
	<mesh_term>Respiratory Tract Diseases</mesh_term>
	<mesh_term>Candesartan</mesh_term>
	<mesh_term>Candesartan cilexetil</mesh_term>
	<criteria>Male female age 18 65 year age inclusive , time signing informed consent . Healthy determine investigator medically qualify designee base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . A subject clinical abnormality laboratory parameter ( ) is/are specifically list inclusion exclusion criterion , outside reference range population study may include investigator consultation Medical Monitor require , agree document find unlikely introduce additional risk factor interfere study procedure . Body weight &gt; = 50 kilogram ( kg ) Body Mass Index within range 19 24.9 kg/meter ( ) ^2 ( inclusive ) . Female subject : eligible participate pregnant ( confirm negative serum human chorionic gonadotrophin test ) , lactate , least one follow condition applies : Nonreproductive potential define : Premenopausal female document tubal ligation , document hysteroscopic tubal occlusion procedure followup confirmation bilateral tubal occlusion , hysterectomy , document bilateral oophorectomy . Postmenopausal define 12 month spontaneous amenorrhea ( questionable case blood sample simultaneous follicle stimulate hormone estradiol level consistent menopause [ refer laboratory reference range confirmatory level ] ) . Females hormone replacement therapy ( HRT ) whose menopausal status doubt require use one highly effective contraception method wish continue HRT study . Otherwise , must discontinue HRT allow confirmation postmenopausal status prior study enrolment . Reproductive potential agrees follow one option list GlaxoSmithKline ( GSK ) Modified List Highly Effective Methods Avoiding Pregnancy Females Reproductive Potential ( FRP ) requirement 30 day prior first dose study medication [ least five terminal halflives OR continue pharmacologic effect end , whichever long ] last dose study medication completion followup visit . GSK Modified List Highly Effective Methods Avoiding Pregnancy FRP . This list apply FRP sex partner , prefer usual lifestyle subject continue abstinent penilevaginal intercourse long term persistent basis : Contraceptive subdermal implant meet effectiveness criterion include &lt; 1 % rate failure per year , state product label . Intrauterine device intrauterine system meet standard operate procedure ( SOP ) effectiveness criterion include &lt; 1 % rate failure per year , state product label . Oral Contraceptive , either combined progestogen alone . Injectable progestogen Contraceptive vaginal ring Percutaneous contraceptive patch Male partner sterilization documentation azoospermia prior female subject 's entry study , male sole partner subject Male condom combine vaginal spermicide ( foam , gel , film , cream , suppository ) follow 3 situation low risk developmental toxicity : Vaccines , Monoclonal antibodies target biology concern , Compounds complete reproductive toxicology package , show signal developmental toxicity . The investigator responsible ensure subject understand properly use follow method contraception . Male subject female partner child bear potential must comply follow contraception requirement time first dose study medication [ least five halflives study medication OR cycle spermatogenesis follow five terminal halflives ] last dose study medication : vasectomy documentation azoospermia , male condom plus partner use one contraceptive option : Contraceptive subdermal implant meet SOP effectiveness criterion include &lt; 1 % rate failure per year , state product label Intrauterine device intrauterine system meet SOP effectiveness criterion include &lt; 1 % rate failure per year , state product label . Oral Contraceptive , either combined progestogen alone Injectable progestogen Contraceptive vaginal ring Percutaneous contraceptive patch Capable give write informed consent , include compliance requirement restriction list consent form . Alanine aminotransferase bilirubin &gt; 1.5x upper limit normal ( ULN ) ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . QT interval correct ( QTc ) &gt; 450 millisecond ( msec ) . No concomitant medication take subject participate study . History regular alcohol consumption within 6 month study define average weekly intake &gt; 21 unit male &gt; 14 unit female . One unit equivalent 8grams alcohol : halfpint ( equivalent 240 milliliter [ mL ] ) beer , 1 glass ( 125 mL ) wine 1 ( 25 mL ) measure spirit . Urinary cotinine level indicative smoke history regular use tobacco nicotinecontaining product within 6 month prior screen . History sensitivity heparin heparininduced thrombocytopenia . History sensitivity study medication , component thereof history drug allergy , opinion investigator Medical Monitor , contraindicate participation . Hypersensitivity candesartan cilexetil excipients . Presence hepatitis B surface antigen positive hepatitis C antibody test result screen within 3 month prior first dose study treatment . For potent immunosuppressive agent , subject presence hepatitis B core . A positive prestudy drug/alcohol screen . A positive test human immunodeficiency virus antibody . Where participation study would result donation blood blood product excess 500 mL within 90 day period . The subject participate clinical trial receive investigational current study : 90 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day . Gastrointestinal disease gastrointestinal surgical history affect absorption investigational drug . Any symptom systolic blood pressure &lt; 95millimeter mercury . Pregnant female determine positive serum human chorionic gonadotrophin test screen prior dosing . Lactating female .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>ATACAND</keyword>
	<keyword>GW615775</keyword>
	<keyword>Candesartan cilexetil</keyword>
	<keyword>relative bio-availability</keyword>
	<keyword>fast</keyword>
</DOC>